Profile data is unavailable for this security.
About the company
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Ecopipam, Olpasiran, Pelabresib, KarXT, Pelacarsen, Seltorexant, Trontinemab, TEV-'749, Tulmimetostat and Vanzacaftor. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.
- Revenue in USD (TTM)2.24bn
- Net income in USD673.24m
- Incorporated2020
- Employees89.00
- LocationRoyalty Pharma PLC110 East 59th StreetNEW YORK 10022United StatesUSA
- Phone+1 (212) 883-0200
- Websitehttps://www.royaltypharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Roivant Sciences Ltd | 158.30m | 4.74bn | 8.42bn | 845.00 | 2.04 | 1.55 | 1.81 | 53.16 | 5.57 | 5.57 | 0.1979 | 7.35 | 0.0367 | 0.8018 | 2.71 | 187,340.80 | 106.95 | -- | 126.66 | -- | 90.32 | -- | 2,916.27 | -- | 27.75 | -- | 0.052 | -- | 103.65 | -- | 487.06 | -- | -- | -- |
Catalent Inc | 4.38bn | -1.04bn | 10.99bn | 16.90k | -- | 3.03 | -- | 2.51 | -5.75 | -5.75 | 24.14 | 20.02 | 0.4268 | 4.88 | 3.01 | 259,230.80 | -10.16 | 0.0124 | -11.61 | 0.014 | 21.75 | 28.93 | -23.81 | 0.0278 | 1.93 | 0.6681 | 0.5765 | -- | 2.77 | 11.71 | -307.42 | -- | 8.44 | -- |
Incyte Corp | 3.86bn | 97.30m | 13.00bn | 2.52k | 190.85 | 4.31 | 70.47 | 3.37 | 0.3536 | 0.3536 | 17.18 | 15.64 | 0.7097 | 3.58 | 5.60 | 1,528,136.00 | 1.79 | 9.07 | 2.31 | 11.02 | 93.66 | 94.97 | 2.52 | 13.68 | 1.84 | -- | 0.0108 | 0.00 | 8.87 | 14.45 | 75.42 | 40.41 | -15.06 | -- |
Biomarin Pharmaceutical Inc | 2.59bn | 256.59m | 13.23bn | 3.40k | 52.40 | 2.50 | 36.46 | 5.11 | 1.33 | 1.33 | 13.28 | 27.77 | 0.3798 | 0.4778 | 3.98 | 761,069.70 | 3.76 | 0.7116 | 4.29 | 0.8079 | 80.07 | 76.30 | 9.91 | 2.05 | 1.95 | -- | 0.1708 | 0.00 | 15.42 | 10.16 | 36.51 | -- | -5.74 | -- |
Viatris Inc | 15.24bn | -646.50m | 13.83bn | 38.00k | -- | 0.7085 | 6.42 | 0.9077 | -0.5433 | -0.5433 | 12.68 | 16.36 | 0.3242 | 2.30 | 5.25 | 401,031.60 | -1.38 | 0.0887 | -1.62 | 0.1061 | 42.78 | 40.29 | -4.24 | 0.2891 | 1.02 | 2.48 | 0.4668 | 560.11 | -5.14 | 6.17 | -97.37 | -30.53 | -16.88 | -- |
Royalty Pharma plc | 2.24bn | 673.24m | 16.47bn | 89.00 | 18.45 | 1.92 | 19.61 | 7.36 | 1.50 | 1.50 | 3.74 | 14.42 | 0.1287 | -- | 76.10 | 25,141,870.00 | 5.92 | 9.57 | 7.77 | 12.42 | -- | -- | 46.02 | 67.80 | -- | -- | 0.4381 | 23.47 | 5.24 | 5.58 | 2,549.50 | -3.80 | 50.99 | -- |
Holder | Shares | % Held |
---|---|---|
Morgan Stanley Investment Management, Inc.as of 31 Mar 2024 | 37.96m | 8.40% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 36.74m | 8.13% |
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 31.19m | 6.90% |
Baillie Gifford & Co.as of 30 Jun 2024 | 16.35m | 3.62% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 15.37m | 3.40% |
Viking Global Investors LPas of 31 Mar 2024 | 11.49m | 2.54% |
Adage Capital Management LPas of 31 Mar 2024 | 10.82m | 2.39% |
Swedbank Robur Fonder ABas of 30 Jun 2024 | 10.81m | 2.39% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 9.10m | 2.01% |
Geode Capital Management LLCas of 30 Jun 2024 | 6.85m | 1.52% |